Abstract
Therapeutic gaps and the low efficiency of immunemodulator drugs have driven to new studies looking forward to develop new and more specific therapeutic strategies to treat Multiple Sclerosis. The natalizumab binds to the ±4 subunit of the integrins ±4²1 and ±4²7, which are expressed in the cell membrane of T and B-lymphocytes. This block impairs the endothelial receptors like VCAM-1 and …